vimarsana.com
Home
Live Updates
Kintor Pharma Announced the Primary Endpoint of Phase II Cli
Kintor Pharma Announced the Primary Endpoint of Phase II Cli
Kintor Pharma Announced the Primary Endpoint of Phase II Clinical Study for KX-826's Treatment of Female Androgenetic Alopecia in China Was Met
DJ Kintor Pharma Announced the Primary Endpoint of Phase II Clinical Study for KX-826's Treatment of Female Androgenetic Alopecia in China Was Met EQS Newswire / 02/12/2022 / 10:34 UTC+8 Kintor
Related Keywords
China ,
Peking ,
Beijing ,
Suzhou ,
Jiangsu ,
Kintor Pharma ,
Jianzhong Zhang ,
Financial Press ,
Kintor Pharmaceutical ,
Department Of Dermatology ,
University People Hospital ,
Kintor Pharmaceutical Limited Pharma ,
Pharma Announced ,
Primary Endpoint ,
Female Androgenetic Alopecia ,
China Was Met ,
Pharmaceutical Limited ,
Peking University People ,
Savin Scale ,
Youzhi Tong ,
Chief Executive Officer ,
Kintor Pharma Announced ,
Financial Press Release ,
Dow Jones Newswires ,
Ukintor ,
Harma ,
Nnounced ,
Rimary ,
Ndpoint ,
Hase ,
Linical ,
Tudy ,
Reatment ,
Emale ,
Androgenetic ,
Alopecia ,